Antibacterial

Crucial research by Neil Osheroff and his lab led to FDA approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name Blujepa, is now approved to treat uncomplicated urinary tract infections and gonorrhea. Read More

Vanderbilt researchers have identified a critical regulatory factor in the bacterium that causes the disease anthrax and has been used as a biological weapon. Read More

New mechanistic details about the DNA-unwinding activity of antibacterial protein targets could lead to the design of better antibiotic medicines. Read More

One small chemical change to an existing antibacterial drug results in a compound that is more effective against its target enzyme in tuberculosis, Vanderbilt researchers have discovered. Read More

Vanderbilt investigators are exploring the shape changes in a multidrug transporter to understand the mechanisms of antibacterial resistance. Read More

Osteomyelitis, a debilitating bone infection most frequently caused by Staphylococcus aureus (“staph”) bacteria, is particularly challenging to treat. Read More

Understanding how bacteria become resistant to quinolone antibiotics could guide strategies for developing new antibacterial drugs. Read More